Nanotechnology has become a cornerstone of modern diagnostics, enabling rapid, sensitive, and reproducible detection of disease biomarkers across point-of-care and laboratory platforms. At Arni Medica, our diagnostics strategy is informed by deep expertise in nanoparticle engineering, nano-enabled biological interactions, and translational formulation science, developed through years of peer-reviewed research.
Scientific Foundation: Nanomaterials and Biological Interfaces
Our Founder, Dr. Parvathaneni’s research in nanotechnology focused on the design, synthesis, and biological evaluation of nanoscale systems, including metallic nanoparticles and polymeric/liposomal carriers.
His work on gold, silver and zinc nanoparticles along with pegylated liposomes demonstrated controlled particle size, surface plasmon behavior, and strong biological interactions, including reproducible antimicrobial activity. These studies established a fundamental understanding of nanoparticle surface chemistry, stability, and bio-interaction, which are directly relevant to diagnostic assay design.
Complementary research on liposomal and polymer-based nanocarriers explored particle uniformity, encapsulation efficiency, and kinetic behavior in biological systems. Pharmacokinetic and toxicological evaluations provided insight into molecular transport, signal persistence, and matrix interactions - parameters that closely parallel signal generation and detection dynamics in diagnostic assays.
Application to Rapid Tests, FIA, and CLIA Platforms
In diagnostics, nanotechnology plays a critical role in signal amplification, assay sensitivity, and turnaround time. Principles derived from nanoparticle research such as surface functionalization, particle size optimization, and binding efficiency are directly applicable to:
Understanding nano–bio interactions enable improved control over antigen–antibody binding efficiency, background signal reduction, and lot-to-lot assay consistency, all of which are critical for reliable diagnostics.
Translational Advantage at Arni Medica
This scientific foundation directly informs Arni Medica’s growing portfolio of rapid tests, FIA, and CLIA assays across oncology, infectious diseases, cardiology, and hepatology. It allows us to:
Building Diagnostics on Science, Not Assumptions
As diagnostics evolve toward faster, more sensitive, and decentralized testing, nanotechnology will continue to be a key enabler. Arni Medica remains committed to translating nano-scale scientific understanding into practical diagnostic solutions that support early detection, disease monitoring, and improved clinical decision-making.
Interested in implementing a science-led oncology diagnostics strategy?
Contact our scientific team at research@arnimedica.com to discuss optimized tumor marker panels and platform solutions.
Research Publications:
P1: https://doi.org/10.1049/iet-nbt.2017.0087Digital Object Identifier (DOI)
P2: https://www.researchgate.net/profile/Madhukiran-Parvathaneni/publication/360246441_Room_Temperature_Synthesis_and_Evaluation_of_silver_nanoparticlespdf/data/626b00b0bfd24037e9dbbfd5/2014-Room-Temperature-Synthesis-and-Evaluation-of-silver-nanoparticles.pdf
P3: https://assets-eu.researchsquare.com/files/rs-1951432/v1/aab3661b-b61c-4696-b912-6b66eab48cd6.pdf
P4: https://doi.org/10.1016/j.biopha.2023.114540
